Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/150986
Title: The expression of HER-2 in colorectal cancer
Authors: Abela, Katrina (2026)
Keywords: Colon (Anatomy) -- Cancer
Rectum -- Cancer
HER-2 protein
Immunohistochemistry
Issue Date: 2026
Citation: Abela, K. (2026). The expression of HER-2 in colorectal cancer (Bachelor's dissertation).
Abstract: Human Epidermal Growth Factor Receptor 2 (HER-2) is a transmembrane growth factor receptor which has an important role in cell proliferation and survival in several solid organ cancers. Its overexpression in breast and gastric malignancies is well-established. However, its expression in colorectal cancer (CRC) is currently being explored in several studies. CRC ranks as the third most common cancer worldwide and the second most common cause of cancer deaths. Although several therapy regimens associated with molecular biomarkers exist for the management of CRC patients, further therapeutic alternatives are necessary, particularly for those with metastatic disease. Recent studies, suggest the HER-2 is overexpressed in around 2 to 5% of CRC cases. However, a validated immunohistochemistry (IHC) staining method and a standardized scoring system for the expression of HER-2 in CRC has not been yet established. This study aims to assess the expression of HER-2 in locally diagnosed CRC cases. In this study, a retrospective cohort of 151 formalin-fixed, paraffin-embedded (FFPE) CRC samples were analysed by IHC using the HercepTest on PT Link and Link 48 staining platform and SP3 antibody optimised on Dako Omnis autostainer. Tumour membrane staining intensity as well as percentage positivity were assessed and compared by using five different scoring systems. Thirteen equivocal cases were further tested using fluorescence in situ hybridization (FISH) analysis for HER-2 gene amplification. A total of 4 (2.6%) cases were identified as HER-2 positive. This study demonstrated that the SP3 antibody outperformed the HercepTest by producing stronger staining intensity and identifying additional HER-2 positive cases. Out of the 5 scoring systems, the Heracles and IRS-p scoring criteria showed the best agreement. The IRS-p scoring system was essential for identifying one of the positive cases. In conclusion, this study supports the potential clinical value of HER-2 testing in CRC, however further research is required to establish a standardised scoring system to improve the accurate identification of HER-2 positive CRC patients who may benefit from anti-HER-2 targeted therapy.
Description: B.Sc. (Hons)(Melit.)
URI: https://www.um.edu.mt/library/oar/handle/123456789/150986
Appears in Collections:Dissertations - FacHSc - 2026
Dissertations - FacHScABS - 2026

Files in This Item:
File Description SizeFormat 
2608HSCMLS420000017663_1.PDF
  Restricted Access
10.52 MBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.